Therefore, LCP1 has promising application prospects as a noninvasive marker of NAFLD/NASH, which is expected to replace liver biopsy to distinguish NAFLD disease stage and detect liver fibrosis degree. This evidence concerns the gene LCP1 and Hepatic fibrosis.